Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus
Simran Grewal, Ninad Zaman, Louis Borgatta, Matthew Nudy, Andrew Foy, Brandon Peterson
Topics & Concepts
MedicineMaceInternal medicineClinical endpointMyocardial infarctionRelative riskAdverse effectDiabetes mellitusRandomized controlled trialStroke (engine)Type 2 diabetesConfidence intervalPlaceboEndocrinologyPathologyPercutaneous coronary interventionMechanical engineeringAlternative medicineEngineeringDiabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management